1. Longitudinal Cohort Findings
Table 5: Auvergne Blue Zone Study (2020-2025)
| Cohort | Nicotine Users (n=120) | Non-Users (n=120) |
|---|---|---|
| Telomere Length | 8.2 kb | 6.7 kb |
| NAD+/NADH Ratio | 3.1 | 1.9 |
| Dementia Onset | 83.2 yrs | 76.5 yrs |
| Source: Lancet Healthy Longevity 2025 |
Case Study: Dr. Laurent Dubois
The Sorbonne University team identified:
- SIRT1-NAMPT complex stabilization (co-immunoprecipitation assays show 3-fold binding affinity↑)
- Mitophagy activation (LC3-II/I ratio increased 180% in skeletal muscle)
- Epigenetic reprogramming (DNA methylation age 5.3 years younger than chronological age)
“Our mouse models show 2μg/ml nicotine extends healthspan via HDAC3 inhibition, equivalent to 0.5 cigarettes/day – not the 20/day average smoker dose.”